At a time when the challenges of providing safe treatment to cancer patients crippled the ability to offer care and reduced revenue industry-wide, this program (less than a year old) is on a current run rate to treat ~250 adaptive patients annually, operating at 125% capacity as compared to pre-COVID times, and helping to backstop volume and revenue loss in other areas of the clinic.
How did the experts at Dana-Farber/Brigham and Women’s Cancer Center do it?
Come hear this cross-functional team discuss building, launching, and growing a stunningly successful on-table, adaptive MR-guided radiation therapy program. They’ll share perspectives from leadership on administrative topics, program building, and clinical experience on the toughest-to-treat patients from both medical and physics viewpoints, as well as their approach to patient recruitment. And they’ll still have time for your questions. Join us!